"Deliver the right cancer treatment to the right patient at the right dose and the right time."
Schwartzberg et al., 2017 ASCO Educational Book
Prostate cancer outcomes vary enormously, both because tumors differ and because access to the right treatment is unequal. The Weiner Research Lab pursues research that addresses both forces at once: the molecular biology that drives a particular cancer's behavior, and the structural factors that determine who gets the right treatment in time.
The lab works across imaging biomarkers, tumor genomics, focal therapy outcomes, and disparities research. Findings have appeared in European Urology, JAMA, Nature Communications, Cancer, and JCO Precision Oncology.
Intersecting research programs aimed at a single question: how do we get every man with prostate cancer the right care at the right time?
Funded in part by the Prostate Cancer Foundation Young Investigator Award, our work on the molecular correlates of prostate-specific membrane antigen helps explain who responds to PSMA-targeted imaging and therapy and who does not.
Genomic predictors that identify which men are best suited for HIFU and other focal approaches, so the right patients get less invasive treatment and the wrong ones do not.
Why outcomes differ across racial and socioeconomic groups, including immune microenvironment differences, access to advanced imaging, and adherence to quality metrics globally.
Patient-reported outcomes, prediction models for treatment regret, and tools that help patients and physicians make confident decisions when options look similar on paper.
Defining who needs intensified therapy after surgery or radiation and who can be safely observed, drawing on systematic reviews and large international datasets.
International variation in adherence to evidence-based prostate cancer quality metrics, and how to close gaps where they exist.
Lab roster, summer 2026.
Principal Investigator
Postdoctoral Fellow
Research Associate
Intern
Intern
Intern
The lab has contributed more than 80 peer-reviewed articles. Selected highlights below; the full list is on PubMed.
Nature Communications · 2026
JCO Precision Oncology · 2025
European Urology Oncology · 2025
Clinical Genitourinary Cancer · 2026
Cancer · 2025
European Urology · 2024
European Urology · 2024
European Urology Oncology · 2024
Nature Communications · 2021
Cedars-Sinai is a major prostate cancer research center, and Dr. Weiner's patients have access to a broad portfolio of trials. Active studies span active surveillance optimization, novel imaging, focal therapy, and management of advanced disease.
Patients interested in trial participation: please mention it at your consultation. Researchers interested in collaboration: email Pranav.Movva@cshs.org.
Postdocs, residents, medical students, and undergraduates are welcome. Trainees work on prostate cancer genomics, PSMA molecular imaging, focal therapy biomarkers, decision science, or disparities research, and most leave with first-author publications.
To apply, email Pranav.Movva@cshs.org with your CV and a paragraph about why this lab. Rolling admissions; we respond within one business day.
Active competitive grants from the field's leading funders, alongside institutional and philanthropic support.
Federal grants take years to land and rarely cover the riskiest, earliest-stage ideas, the ones most likely to shift the field. Philanthropy fills that gap. A gift of any size accelerates the work.